# A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06172478/  
OnCo record `nct06172478` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Patritumab deruxtecan in melanoma and cervical cancer, run by Daiichi Sankyo, now recruiting.

## Summary

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors is a phase 2 interventional study registered as NCT06172478 by Daiichi Sankyo, with 740 participants planned, started 2024-02-26 and due to reach its primary completion in 2027-09-01. Interventions recorded: HER3-DXd. Conditions listed: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06172478
- Phase: 2
- Setting: HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Daiichi Sankyo
- Enrolled: 740

## Sources

- ClinicalTrials.gov NCT06172478: https://clinicaltrials.gov/study/NCT06172478

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Patritumab deruxtecan](https://onco.cc/drugs/patritumab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct06172478.json